PMID,Title,Journal,Year
39226729,FDA-approved antivirals ledipasvir and daclatasvir downregulate the Src-EPHA2-Akt oncogenic pathway in colorectal and triple-negative breast cancer cells.,Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,2024
